Top 10 Major Companies in the Taiwan Ataxia Market | Insights & Key Players 2026

Q: How do global players like Biogen maintain their lead in Taiwan?

Multinational giants maintain their lead by securing Orphan Drug Designations, managing large-scale international clinical trials, and integrating their therapies into the NHI framework.

Q: What role do domestic players like Steminent and Everfront Biotech play in treatment?

Regional players are the major drivers of innovation, leading world-class stem cell research and developing targeted orphan drugs for the local population.

Q: Which organization leads the Friedreich’s Ataxia segment in the Taiwan market?

Biogen is the key provider for this segment, following breakthrough treatments which represent the first FDA-approved therapies for this specific form of ataxia.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA12153

Publication Date: Apr 2026

Top 10 Major Companies in the Taiwan Ataxia Market

The Taiwan Ataxia market is a combination of global pharmaceutical companies and prominent local firms, all competing for a higher market share through strong regional presence and innovative treatment development. Key players in the market include Steminent Biotherapeutics Inc., Everfront Biotech Inc., ALPS Biotech Co., Ltd., Sanofi, Takeda Pharmaceuticals Taiwan, and Roche (F. Hoffmann-La Roche Ltd.).

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Taiwan Ataxia market.

View Main Report Schedule Analyst Call

Taiwan Ataxia Market Overview

According to 6Wresearch, the Taiwan Ataxia market is expanding further, due to growing awareness levels and the prevalence of neurodegenerative disorders. Ataxia is a disorder that affects motor functions, and severely affects the quality of life. The market of ataxia is fuelled by the need to develop effective treatments, along with increasing focus on neurological health.

Furthermore, the growth of healthcare infrastructure in Taiwan is driving the growth of this market, with initiatives to innovate and develop special treatments for such disorders are gaining traction. Organizations are investing heavily in R&D, particularly in regenerative medicine and stem cell therapy, to cater to the needs of individuals suffering from Ataxia.

Competitive Landscape

The competitive landscape of the Taiwan Ataxia Industry is categorized by multinational pharmaceutical companies that use their superior R&D capabilities to bring innovations in the treatment of neurodegenerative disorders, alongside an expanding domestic biotech sector specializing in orphan drugs. Moreover, the rise in the number of local and international players has resulted in innovations in Ataxia care for patients.

Below is the list of leading players in the Taiwan Ataxia Market:

1. Steminent Biotherapeutics Inc.

Company Name	Steminent Biotherapeutics Inc.
Established Year	2009
Headquarters	Taipei, Taiwan
Official Website	Click Here

Steminent is a global pioneer in regenerative medicine, leading the development of stem cell therapy in advanced clinical trials for Ataxia.

2. Everfront Biotech Inc.

Company Name	Everfront Biotech Inc.
Established Year	2008
Headquarters	New Taipei City, Taiwan
Official Website	Click Here

Everfront Biotech specializes in orphan drug development, which targets the blood-brain barrier to treat Spinocerebellar Ataxia through molecule delivery.

3. Biogen Taiwan

Company Name	Biogen Taiwan
Established Year	2016 (Local entity) / 1978 (Global)
Headquarters	Taipei, Taiwan
Official Website	-

Biogen is a dominant global leader in neuroscience, currently leading the Ataxia segment in Taiwan following the introduction of SKYCLARYS.

4. Sanofi Taiwan

Company Name	Sanofi Taiwan
Established Year	1973 (Legacy presence)
Headquarters	Taipei, Taiwan
Official Website	Click Here

Sanofi remains a major player by providing specialized neuro-supportive therapies and participating in regional research collaborations for rare movement disorders.

5. Roche (F. Hoffmann-La Roche Ltd.) Taiwan

Company Name	Roche (F. Hoffmann-La Roche Ltd.) Taiwan
Established Year	1967 (Taiwan presence)
Headquarters	Taipei, Taiwan
Official Website	Click Here

Roche leverages its extensive R&D to focus on antisense oligonucleotide therapies that target the genetic roots of inherited ataxias.

6. Takeda Pharmaceuticals Taiwan

Company Name	Takeda Pharmaceuticals Taiwan
Established Year	1962
Headquarters	Taipei, Taiwan
Official Website	Click Here

Takeda utilizes its "Rare Disease Excellence" framework to ensure Ataxia patients have access to metabolic and neurological supportive treatments.

7. Novartis Taiwan

Company Name	Novartis Taiwan
Established Year	1996 (Merger)
Headquarters	Taipei, Taiwan
Official Website	Click Here

Novartis provides a range of pharmaceutical solutions focused on managing the complex symptomatic progression of cerebellar atrophy.

8. PTC Therapeutics Taiwan

Company Name	PTC Therapeutics Taiwan
Established Year	2020 (Expanded presence) / 1998 (Global)
Headquarters	Taipei, Taiwan
Official Website	Click Here

PTC Therapeutics is an emerging leader, focusing on gene-related therapies and collaborating with National Taiwan University for clinical data.

9. Everest Pharmaceuticals

Company Name	Everest Pharmaceuticals
Established Year	1992
Headquarters	Taipei, Taiwan
Official Website	Click Here

Everest serves as a critical distributor and manufacturer for various supportive medications and vitamins used in the long-term management of ataxia symptoms.